arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Moleculin Biotech, Inc.

MBRX
$0.53 ▼ -0.03 (-5.20%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
45 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Moleculin Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.0M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -51.6% ↘
FCF / Share $-1.17 ↗
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

45-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-12.85M
↓ -99.6% —
FCF / Share Free cash flow per share
$-1.17
↑ +20.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
1
Cash Quality ↓
47

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 11 years · 45 quarters